Finding Efficacy in a Safety Trial: Empagliflozin and Cardiovascular Death.
From Brigham and Women's Hospital, Divisions of Cardiovascular and Preventive Medicine, Boston, MA (B.M.E.); and University of Colorado School of Medicine, Aurora (W.R.H.). beverett@partners.org.
Brendan M
BM
Everett
From Brigham and Women's Hospital, Divisions of Cardiovascular and Preventive Medicine, Boston, MA (B.M.E.); and University of Colorado School of Medicine, Aurora (W.R.H.).
William R
WR
Hiatt
D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards; D003643:Death; D017277:Drug Approval / Q000379:methods; D005960:Glucosides / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; C570240:empagliflozin
cardiovascular death; diabetes mellitus, type 2; myocardial infarction; stroke